编者按：一年一度的肿瘤学奥林匹克盛会——2019年美国临床肿瘤学会（ASCO）年会将于5月31日至6月4日在芝加哥举行。预览会议日程，当地时间6月3日8:00 AM - 11:00 AM将在Arie Crown Theater举行肾癌/尿路上皮癌的3场重磅大会发言及讨论，MD安德森癌症中心华人学者高建军教授也将带来一场大会口头报告。现整理Oral Abstract Session如下。《肿瘤瞭望》与您共赴芝加哥学术盛宴，网罗国际肿瘤学新知，传递中国肿瘤学新声！
转移性肾细胞癌的前线治疗进展
Brian I. Rini教授
克利夫兰诊所陶西癌症研究所
Abstract 4500
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
KEYNOTE-426研究：帕博利珠单抗联合阿西替尼对比舒尼替尼一线治疗转移性肾癌，IMDC中高危风险及肉瘤亚组的数据分析
高建军教授
德克萨斯大学MD安德森癌症中心
Abstract 4501
A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy， metastasectomy or post-treatment biopsy (Bx).
一项初步随机研究，评估纳武单抗或纳武单抗+贝伐珠单抗或纳武单抗+伊匹单抗在转移性肾细胞癌患者减瘤性切除、转移灶切除或活检后的治疗
Leonard Joseph Appleman教授
匹兹堡大学医学院希尔曼癌症中心
Abstract 4502
Randomized， double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
E2810试验：一项随机、双盲3期研究，评估培唑帕尼在转移性肾细胞癌转移灶切除后无疾病进展患者中的治疗
转移性尿路上皮癌的新治疗策略
Jonathan E. Rosenberg教授
纪念斯隆-凯特琳癌症中心
Abstract 4503
CALGB 90601 (Alliance): Randomized， double-blind， placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.
CALGB 90601 (Alliance)试验：比较吉西他滨和顺铂与贝伐单抗或安慰剂治疗转移性尿路上皮癌患者的随机、双盲、安慰剂对照3期试验
Matt D. Galsky教授
纽约西奈山伊坎医学院
Abstract 4504
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
HCRN GU14-182研究：对比转移性尿路上皮癌患者一线化疗后维持帕博利珠单抗与安慰剂治疗的随机双盲2期研究
Daniel Peter Petrylak教授
耶鲁大学医学院
LBA4505
EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
EV-201: 抗体偶联药enfortumab vedotin单药治疗既往接受过铂类和免疫检查点抑制剂治疗的局部晚期或转移性尿路上皮癌
膀胱癌/肾癌局部治疗和系统治疗的整合
Thomas W. Flaig教授
科罗拉多大学医学院
Abstract 4506
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized， muscle-invasive bladder cancer.
SWOG S1314：利用共表达外推检测系统（COXEN）探索局部肌层浸润性膀胱癌新辅助化疗的随机2期研究
Karim Fizazi教授
巴黎大学苏德分校古斯塔夫·罗西研究所
Abstract 4507
Randomized trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced bladder cancer after radical cystectomy.
局部晚期膀胱癌患者膀胱根治术后辅助化疗与辅助放疗的随机试验。
Arnaud Mejean教授
巴黎笛卡尔大学乔治蓬皮杜欧洲医院
Abstract 4508
Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.
Carmena试验：转移性肾细胞癌中的减瘤性肾切除术，关注IMDC中危人群
京公网安备 11010502033352号